Eos BioInnovation is an investment firm focused on launching and developing start-ups in the field of regenerative medicine. The firm specializes in transforming innovative concepts into viable businesses by incubating and supporting early-stage companies that emerge from leading academic laboratories and research institutions. Eos BioInnovation aims to foster a strong track record of success for its clients by facilitating the development of therapies and technologies in regenerative medicine.
Autoimmunity BioSolutions is working on a next-generation immuno-corrective therapy that restores normal immune function in a genetically defined subgroup of autoimmune patients, where the autoimmune pathology is driven by an SNP.
HDAX Therapeutics
Seed Round in 2024
HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. By addressing the root causes of these conditions, the company seeks to improve patient outcomes significantly. Their approach involves a unique targeted therapeutics platform that utilizes a two-site binding mechanism for HDAC6, which allows for the delivery of treatments that are both safe and effective. This strategy is designed to meet the substantial unmet medical needs associated with neuropathies and cardiometabolic diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.